| Document |
Document Title |
|
WO/2022/009695A1 |
The present invention provides: an alkoxide compound represented by general formula (1); a thin film-forming material containing said compound; and a method for manufacturing a thin film. (In the formula, R1 and R2 each independently rep...
|
|
WO/2022/004506A1 |
The present invention addresses the problem of providing a novel compound which has satisfactory solubility in solvents, has high storage stability (solution stability) during refrigeration or freeze storage, and is usable as a crosslink...
|
|
WO/2022/001515A1 |
Disclosed is a preparation method for a cardanol modified polyamine curing agent having high anticorrosive performance, comprising subjecting cardanol, paraformaldehyde and an amine compound to a Mannich reaction, adding a water-soluble ...
|
|
WO/2021/260118A1 |
The invention relates to mixtures of propoxylated 4-toluidines containing two or more different di- or tri-propoxylated or higher propoxylated p-toluidines in specific weight ratios, to methods for preparing them and to their use as poly...
|
|
WO/2021/255180A1 |
The present invention relates to 2-aminoethanol, piperazine and L- lysine salts of Bempedoic acid and processes for the preparation thereof.
|
|
WO/2021/251337A1 |
CB-7 exhibits a weak TLR7 inhibiting effect in normal mice. The present invention provides a novel compound with a stronger TLR7 inhibiting effect than CB-7, a pharmaceutically acceptable salt of said compound, or a prodrug of said compo...
|
|
WO/2021/185072A9 |
Disclosed in the present invention are a crystal form of aromatic vinyl derivatives, and a preparation method therefor and the use thereof. Specifically disclosed in the present invention are crystal form A, crystal form B and crystal fo...
|
|
WO/2021/236771A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2021/236395A1 |
CB-0406 choline salt, especially in crystalline form and as an ansolvate, methods of preparing it, compositions containing it, and its pharmaceutical uses.
|
|
WO/2021/233752A1 |
The present invention is directed to compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprisin...
|
|
WO/2021/236759A2 |
This disclosure relates to crystalline bis(4-hydroxy-N,N-di-n-propyltryptammonium)fumarate tetrahydrate (4-HO-DPT fumarate-4H2O) and to crystalline 4-hydroxy-N,N-di-n-propyl-tryptammonium chloride (4-HO-DPT chloride). Compositions contai...
|
|
WO/2021/236394A1 |
CB-0406 tromethamine salt, especially in crystalline form and as an ansolvate, methods of preparing it, compositions containing it, and its pharmaceutical uses.
|
|
WO/2021/219647A1 |
The present invention relates to a method for preparing paracetamol continuously, comprising a nitration step or a nitrosation step so as to obtain p-nitrophenol or p-nitrosophenol, respectively. The p-nitrophenol or p-nitrosophenol can ...
|
|
WO/2021/214762A1 |
The invention provides an isolated material, or a phenolate form of at least one phenol- containing active material, wherein the isolated material comprises one or more phenolate species and a counter ion (a cation) in the form of a meta...
|
|
WO/2021/212880A1 |
Disclosed is a method for preparing nicotine, in particular, a method for preparing nicotine by using nicotinate as a starting material to undergo a five-step reaction. The specific synthetic steps comprise: (1) performing a condensation...
|
|
WO/2021/206513A1 |
The present invention relates to a pharmaceutical composition for preventing or treating muscular weakness-related diseases, comprising alverine, 4-hydroxy alverine, a derivative thereof, or a pharmaceutically acceptable salt thereof. Wh...
|
|
WO/2021/158637A9 |
Various aspects of the present invention relate to cationic latex emulsions, methods of making the same, various materials including the cationic latex emulsion such as asphalt emulsions, and methods of making the asphalt emulsions. A ca...
|
|
WO/2021/193963A1 |
Provided is an absorption liquid for separating and recovering carbon dioxide from gas containing carbon dioxide, the absorption liquid containing an alkanolamine compound represented by formula (1) and accounting for 30-70 mass% of the ...
|
|
WO/2021/175886A1 |
The present invention relates to a fusing agent, comprising a compound of formula (I), a three-dimensional (3D) printing kit including the compound of formula (I) and A method for three-dimensional (3D) printing, including selectively ap...
|
|
WO/2021/163811A1 |
Provided herein are compositions including polymeric binder or a salt thereof, high molecular weight polymer, pharmaceutically active agent and a low molecular weight cross-linking agent, methods for using the compositions to coat a subs...
|
|
WO/2021/152281A1 |
The invention relates to a Mannich base useful as an epoxy curative agent. In particular, the present invention is directed to a Mannich base derived from furfuryl alcohol, or a homopolymer or co-polymer thereof, an epoxy resin curative ...
|
|
WO/2021/149502A1 |
Provided is a composition that has a suitable viscosity for coatability and discharge properties, can be fired at a low temperature, and yields an extremely small amount of ash after being fired. A composition according to the present ...
|
|
WO/2021/150559A1 |
The invention provides methods for treating cancer in a patient comprising administering dosing regimens of (S,S)-(HO)2DEHSPM that unexpectedly reverse or reduce the onset of severe liver toxicity and improve patient safety profiles.
|
|
WO/2021/130168A1 |
This invention relates to an ophthalmic formulation comprising lifitegrast, an amino compound, a tonicity-adjusting agent and water, wherein the formulation has an osmolality of 150-330 mOsm/kg. The invention also relates to lifitegrast ...
|
|
WO/2021/126892A1 |
A method of oxygen scavenging, the method (i) providing an oxygen scavenger composition; and (ii) adding the oxygen scavenger composition to an aqueous feed and/or a hydrocarbon feed of a hydrocarbon processing system.
|
|
WO/2021/116874A1 |
The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dio
xol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-
1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan...
|
|
WO/2021/114166A1 |
A process for preparing a N-substituted alkanolamine of formula (I) and/or a N-substituted diamine of formula (II) from glycolaldehyde is provided, which comprises reacting glycolaldehyde with an aminating agent of formula (III) in a sol...
|
|
WO/2021/113983A1 |
Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.
|
|
WO/2021/105337A1 |
The present invention relates to a process for synthesizing large scale a compound of formula (I), or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and tr...
|
|
WO/2021/106678A1 |
This acylphosphine composition contains a cation represented by formula (1) and two or more types of anion including an acylphosphine anion represented by formula (2). The ratio of the molar equivalent amount of the cation relative to th...
|
|
WO/2021/099456A1 |
The present invention relates to a process for the conversion of propylene oxide to 1-amino-2- propanol and/or di(2-hydroxypropyl)amine comprising (i) providing a catalyst comprising a zeolitic material comprising YO2 and optionally comp...
|
|
WO/2021/098136A1 |
A class of multi-mixed composite salt monomers having anti-oxidation stability and polybenzodiazole liquid crystal polymers, and preparations and applications thereof. The structure of the multi-mixed composite salt monomer is represente...
|
|
WO/2021/093426A1 |
A method for synthesizing hydroxybenzylamine, relating to the technical field of organic synthesis. The principle of the method comprises: a demethylation reaction of methoxybenzylamine under the effect of hydrobromic acid. The present i...
|
|
WO/2021/095091A1 |
The present invention relates to provision of: an intermediate which enables, for example, the achievement of an aminoaryl derivative by being reacted, as a nucleophilic reaction reagent, with an electrophilic reagent or the like, withou...
|
|
WO/2021/095398A1 |
The present invention provides: a novel and useful compound for performing various treatments on a hydrogen bond material such as a biological sample; and a hydrogen bond material treating agent. This organic ammonium salt, which is so...
|
|
WO/2021/088456A1 |
The invention uses a production method of first generating a monoquaternary ammonium salt intermediate, and then generating a target biquaternary ammonium salt product. The whole production process achieves continuous production of conti...
|
|
WO/2021/076944A1 |
Embodiments of a composition of the present invention for scavenging sulfides from hydrocarbon fluids and water generally include diaminol/diaminacetal provided in a chemical system, wherein the diaminol/diaminacetal is prepared by react...
|
|
WO/2021/052271A1 |
A magnolol derivative and a preparation method therefor and an application thereof. The magnolol derivative has a structure represented by formula (1). The magnolol derivative has good water solubility, is colorless and transparent after...
|
|
WO/2021/052270A1 |
The present invention relates to the field of honokiol derivatives. Disclosed are a honokiol derivative, a preparation method therefor and the use thereof, wherein the derivative has a structure as shown in formula (I). The honokiol deri...
|
|
WO/2021/050538A1 |
This document provides methods and materials for increasing the level of phosphorylated AMPK. For example, compounds (e.g., organic compounds) having the ability to increase the level of phosphorylated AMPK within cells, formulations con...
|
|
WO/2021/047490A1 |
Disclosed in the present invention is a method for preparing dexibuprofen, comprising: (1) after adding toluene into a reaction kettle, adding ibuprofen and n-octyl-d-glucamine, heating to 76 to 80°C, keeping the temperature and reactin...
|
|
WO/2021/039843A1 |
The present invention addresses the problem of providing: a (poly)amine compound which is particularly useful as a material for forming a film for lithography or as a material for forming an optical component; a resin which is obtained u...
|
|
WO/2021/039023A1 |
The present invention provides, inter alia, a novel method for producing a compound represented by formula (I) and a novel method for producing a compound represented by formula (B) or a salt thereof, which are intermediates in the produ...
|
|
WO/2021/024271A1 |
A continuous process(200) for manufacture of dl-2-nitro-1-butanol from 1-nitropropane is disclosed. The process mixes aqueous solution of sodium hydroxide (A) and a solution of 1-nitropropane (B) dissolved in alcohol(203) at a first mola...
|
|
WO/2021/003462A1 |
The present invention relates to novel cationic lipids of formula I, and more specifically formula IV. These are used, for example, in liposomes for the delivery of nucleic acids to cells.
|
|
WO/2020/263994A1 |
The present invention discloses a liquid, propellant-free pharmaceutical formulation and a method for administering a pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutic...
|
|
WO/2020/257940A1 |
The present application provides furosemide analogues of the general formula Z having activity as anti-Aβ aggregation agents and/or as inhibitors of Aβ induced neuroinflammation. Formula Z These compounds are useful in preventing, dela...
|
|
WO/2020/249427A1 |
A process for the conversion of glycolaldehyde with an aminating agent in the presence of hy-5 drogen and of a catalyst, wherein the conversion is carried out in the gas phase.
|
|
WO/2020/248127A1 |
A borohydride reduction stabilizing system and a method for reducing an ester to an alcohol. The borohydride reduction stabilizing system comprises: a borohydride reducing agent and a stabilizing agent for stabilizing the borohydride red...
|
|
WO/2020/249428A1 |
A process for the manufacture of ethyleneamines and ethanolamines, comprising the steps of (i) converting a glycolaldehyde derivative of formula (II), in which R2, R3 are - the same or different -hydrogen, alkyl, such as C1-6-alkyl, or c...
|
